Collected Transatlantic Experience From the PERICLES Registry: Use of Chimney Grafts to Treat Post-EVAR Type Ia Endoleaks Shows Good Midterm Results

Sonia Ronchey, MD, PhD1, Stefano Fazzini, MD, PhD1, Salvatore Scali, MD2, Giovanni Torsello, MD3, Paul Kubilis, MD2, Frank Veith, MD4,5, Konstantinos P. Donas, MD3, Felice Pecoraro, MD4,6, and Nicola Mangialardi, MD7

Abstract
Purpose: The aim of this retrospective analysis was to evaluate the performance of the chimney (ch) technique in the treatment of type Ia endoleaks after standard endovascular aneurysm repair (EVAR). Methods: Between January 2008 and December 2014, 517 chEVAR procedures were performed in 13 US and European vascular centers (PERICLES registry). Thirty-nine patients (mean age 76.9 ± 7.1 years; 33 men) were treated for persistent type Ia endoleak and had computed tomography angiography or magnetic resonance angiography follow-up at >1 month. Endurant abdominal stent-grafts were used in the 20 cases. Single chimney graft placement was performed in 18 (46%) patients and multiple in 21 (54%). Overall, 70 visceral vessels were targeted for revascularization. Results: Technical success was achieved in 35 (89.7%) cases; 3 persistent type Ia endoleaks and 1 chimney graft occlusion were detected within the first 30 days. Thirty-day mortality was 2.6%. Two other deaths (not aneurysm related) occurred during a mean follow-up of 21.9 months (0.23–71.3). Primary patency of the chimney grafts was 94.3% at 36 months. In a subgroup analysis comparing Endurant to other stent-grafts, no significant differences were observed regarding persistent endoleak [1/20 (5%) vs 2/19 (11%), p=0.6] or reintervention [1/20 (5%) vs 0/19 (0%)]. Conclusion: The present series demonstrates that chEVAR in the treatment of post-EVAR type Ia endoleaks has satisfactory results independent of the abdominal and chimney graft combinations. Midterm results show that chEVAR is an effective method for treating type Ia endoleaks.

Keywords
abdominal aortic aneurysm, chimney graft, chimney technique, endoleak, endovascular aneurysm repair, juxtarenal aortic aneurysm, parallel graft, pararenal aortic aneurysm, periscope graft, snorkel graft

Introduction
Type Ia endoleak after previous endovascular aneurysm repair (EVAR) has an incidence of 3.5% to 15.5% and is due to inadequate proximal sealing of the graft.1,2 It occurs more commonly when the graft is implanted outside the instructions for use or in complex anatomy (short, conical, large diameter, or severely angulated neck). However, even when the first implantation is performed in favorable anatomy, over time proximal neck degeneration can lead to sac reperfusion owing to lack of sealing and/or graft migration.3–6 Treatment of type Ia endoleak is mandatory as sac reperfusion is responsible for increasing aortic diameter and the risk of rupture.
Open conversion with graft explantation is a highly risky procedure, especially in fragile patients, and has a mortality >10% even in experienced centers.7–9 Endovascular options include the use of cuffs, Palmaz stents, endoanchors, coils, and glues; these approaches have a perioperative mortality close to zero but unsatisfactory late results in terms of rein-tervention and risk of rupture.10–12

When it is necessary to create a new neck above the renal arteries, custom fenestrated devices and chimneys are the only options. The choice is strictly related to the anatomy, clinical setting (ie, urgent/emergency), center-specific experience, material availability, and risk profile of the patient.

The aim of the present study was to analyze the outcomes of type Ia endoleak treatment using chimney EVAR (ch-EVAR) as collected in the PERICLES Registry (PERformance of the chimney technique for the treatment of Complex aortic pathologiES).13

### Methods

#### Study Cohort

Between January 2008 and December 2014, 517 ch-EVAR procedures were performed in 13 US and European vascular centers, which all had experience treating >10 patients with complex abdominal aortic pathologies using this technique. Of these, 39 patients (mean age 76.9±7.1 years; 33 men) were treated in elective or urgent procedures for type Ia endoleak and had at least 1 postoperative computed tomography angiography (CTA) or magnetic resonance angiography (MRA) scan beyond 1 month post EVAR. The original aortic aneurysms were juxtarenal in 32 (82%) and pararenal in 7 (18%). The endografts used in the initial EVAR procedure had suprarenal fixation in 29 (74%) and infrarenal fixation in 10 (26%).

The patients provided informed consent for the ch-EVAR procedure. Mean time from the previous EVAR to ch-EVAR was 7.0±1.3 years. All the type Ia endoleaks were related to neck degeneration with migration ≤5 mm in 14 (36%) cases or >5 mm in 25 (64%). All patients were considered high-risk candidates for open conversion (ie, banding or endograft explantation with aortic repair) and were classified as American Society of Anesthesiologists class III/IV because of severe comorbidities. Thirty (77%) patients were asymptomatic and treated in the elective setting, while 9 (23%) were treated urgently owing to abdominal/lumbar pain. The CT scans in these latter patients showed rapid increase in diameters and signs of impending rupture (blister, thin wall). Patient characteristics and preoperative anatomic characteristics are summarized in Table 1.

#### Treatment Procedure

The selection of chimney graft (CG) type [self-expanding covered stents (SECS) or balloon-expandable covered stents (BECs) with bare metal stents (BMS)] and aortic stent-graft was based on each institution’s clinical practice and the surgeon’s preference, as were CG configuration (chimney/snorkel or periscopes), access sites, and main graft oversizing (range 25% to 35%). All commercially available abdominal and even thoracic stent-grafts (Table 2) were used in different combinations with CGs. The most often implanted aortic cuff (20, 51%) was the Endurant (Medtronic, Minneapolis, MN, USA). Single CGs were placed in 18 (46%) patients and multiple in 21 (54%), mostly doubles (14/21), for a total of 70 target arteries revascularized. Most of the CGs were placed in the renal arteries (57/70, 81%), including 1 accessory renal artery.

#### Antiplatelet Therapy and Follow-up Protocols

Follow-up strategies and medication protocols were similar for all centers and predefined by the PERICLES Registry collaborators. The recommended postoperative antiplatelet therapy was aspirin (100 mg) and clopidogrel 75 mg daily for at least 2 months; clopidogrel 75 mg alone was used in patients under anticoagulation. All patients had a CTA during the month after operation and were scheduled for outpatient follow-up with physical examination and CTA at 6 and 12 months and annually thereafter. Another CTA was performed at 3 months if type Ia endoleak

### Table 1. Patient Demographics, Comorbidities, Indications, and Preoperative Anatomic Characteristics.

<table>
<thead>
<tr>
<th>Description</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>76.9±7.1</td>
</tr>
<tr>
<td>Men</td>
<td>33 (85)</td>
</tr>
<tr>
<td>ASA III</td>
<td>20 (51)</td>
</tr>
<tr>
<td>ASA IV</td>
<td>19 (49)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>10 (26)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>37 (95)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>21 (54)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>21 (54)</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>20 (51)</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>6 (21)</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>13 (33)</td>
</tr>
<tr>
<td>Chronic renal insufficiency</td>
<td>13 (33)</td>
</tr>
<tr>
<td>Aneurysm features</td>
<td></td>
</tr>
<tr>
<td>Juxtarenal</td>
<td>32 (82)</td>
</tr>
<tr>
<td>Pararenal</td>
<td>7 (18)</td>
</tr>
<tr>
<td>Infrarenal neck diameter, mm</td>
<td>27.0±5.2</td>
</tr>
<tr>
<td>Infrarenal neck length, mm</td>
<td>3.9±4.0</td>
</tr>
<tr>
<td>Diameter, mm</td>
<td>71.5±29.0</td>
</tr>
</tbody>
</table>

Abbreviations: AAA, abdominal aortic aneurysm; ASA, American Society of Anesthesiologists.

*Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage).
was seen at completion angiography. Contrast-enhanced ultrasound associated with a native CT or, alternatively, MRA was used in case of renal insufficiency.

Outcomes

The primary outcome was technical success, defined as successful main and parallel graft deployment at the intended site, patency of the CGs, and absence of type Ia endoleak at completion angiography. The secondary outcomes were 30-day mortality, the incidence of type Ia endoleak, primary patency of the CGs, and freedom from reintervention.

Statistical Analysis

Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage). Kaplan-Meier analysis was used to estimate the survival rate and CG patency; the estimated rates are presented with the 95% confidence intervals (CI). The threshold of statistical significance was p<0.05. The statistical analysis was performed with SPSS software (version 22.0; IBM Corporation, Armonk, NY, USA).

Results

Technical success was achieved in 35 (90%) cases. No evidence of any type of endoleak was observed in the postoperative control (Table 2), but 3 (8%) persistent type Ia endoleaks and 1 (3%) CG occlusion were detected within the first 30 days (Table 3). Two of the endoleaks (gutters-related with a stable diameter) were treated conservatively under radiologic surveillance, while 1 patient with triple CG placement and increasing aortic diameter was successfully treated using Onyx embolization 7 months postoperatively (freedom from reintervention 97.4%).

No early/late procedure-related death occurred. However, 1 patient died due to acute cardiac failure within the first month (30-day mortality 2.6%), while 2 patients died due to pneumonia during follow-up (overall mortality 7.7%; Figure 2A).

The mean follow-up of this patient cohort was 21.9 months (range 0.23–72.3). Primary patency of the CGs was 94.3% (66/70) at 36 months. Based on the type of CG, the estimated overall primary patency of CGs at 24 months was 86.1% (Figure 2B): 100% for SECS and 77.2% for BECS and BMS. No difference was observed in CG primary patency considering the different types of main graft (Endurant 85% vs 87.5% for other models).
No statistically significant difference was noted in terms of freedom from type Ia endoleak at follow-up between chEVAR performed using an Endurant device and other devices [1/20 (5%) vs 2/19 (11%), p=0.6] or reintervention [1/20 (5%) vs 0/19 (0%)].

The pre/post maximum sac diameters were 71.5±29.0 mm and 69.9±27.5 mm, respectively, for a 1.6-mm postoperative sac shrinkage (p=0.486). The newly created sealing zone increased by 16.5 mm. The pre/post infrarenal neck lengths were 3.9±4.0 mm and 20.4±4.2 mm, respectively.

**Discussion**

The incidence of type Ia endoleak has been reduced during the last few years thanks to improvements in stent-graft designs and better patient selection; nonetheless, the rate is...
still not negligible, ranging from 3.5% to 15.5% in the latest series.1,2 While intraoperative type Ia endoleaks can resolve spontaneously in some cases, justifying a watchful waiting strategy, late type Ia endoleaks need to be treated because they are strictly associated with sac growth, and ultimately, to aneurysm rupture.14–16 At the moment there is no consensus about the optimal treatment.

Open conversion represents a valid and effective option, but it carries a high risk of perioperative mortality, which increases dramatically in the case of rupture.17–19 The possibility of performing a partial conversion or entirely sparing the endograft has been shown to reduce the risk of the open procedure,20 but endovascular treatment, when feasible, certainly represents a better option for this high-risk population.21–23

Cuffs are a reasonable approach to treat distal migration with a residual infrarenal neck, but different strategies are necessary when the graft is still in place. Embolization with Onyx and/or coils has been described as an effective option in selected cases. Ameli-Renani et al24 recently reported the results of 27 type Ia endoleak embolization procedures in 25 patients: despite an early technical success of 100%, the recurrence rate in this series was as high as 32%. The authors noted some anatomic patterns that increased the risk for late recurrence, in particular, wide endoleak cavities with a large entrance in the aneurysm sac. Moreover, in this situation there is always a certain risk of Onyx reflux.25

Endoanchors are designed to enhance endograft proximal fixation and sealing. The ANCHOR registry compared the prophylactic use of the anchors with their use in the treatment of proximal aortic neck complications and found better technical success (absence of a type Ia endoleak at completion angiography) for the former (89.7% vs 80.5%, respectively).11

Fenestrated grafts are a valid alternative to correct endoleaks alone or in associated with proximal neck evolution. However, there are technical problems related to the presence of the previously implanted stent-grafts (kinking/stenosis/tortuosity of the leg, suprarenal stent in front of the renal arteries, difficult visualization of the fenestration markers) and to the large diameter of the custom devices. The technical success of these procedures is between 58.3% and 92.3%, and the immediate target vessel failure is 5.4% to 8%.26–28

The chimney technique seems a feasible and relatively safe option in endoleak treatment. The Münster group29 reported an experience with 18 EVAR patients with juxtarenal aneurysms and type I endoleak treated using primarily the Endurant stent-graft in conjunction with the Advanta stent-graft as the chimney. Primary CG patency was 94.4% and secondary patency was 100%. The Zurich group30 reported 24 type I endoleaks, including some thoracoabdominal cases and 7 treated urgently (5 symptomatic, 2 with rupture). Of the 55 target vessels, 31 received chimneys and 24 sandwich/periscope configurations, with most cases treated using a combination of Excluder and Viabahn. Technical success was 96%, but all target vessels were revascularized. The estimated parallel graft patency was 94%. Tanious et al31 treated 19 cases with 100% technical

Figure 2. Kaplan-Meier curves of (A) chimney graft primary patency in 39 patients and (B) overall survival.
success and CG patency at 17 months. Youssef et al32 successfully treated 10 post-EVAR type I endoleaks using chimneys and the Nellix endovascular aneurysm sealing system; all repairs were patent at 8 months.

The current retrospective analysis adds further support to the efficacy of this off-the-shelf strategy, even in urgent cases (23% of the series). The presence of a previous suprarenal fixation did not negatively affect cannulation of the target vessel or the late patency. The rate of endoleak recurrence was low (3 cases), and only 1 case required correction due to sac expansion.

When compared to the entire PERICLES registry,13 the results here are similar in terms of chimney patency (94.3% vs 94.1%) and incidence of immediate type Ia endoleak (92.3% vs 92.1%). While there was no difference in terms of performance among the aortic components, SECS showed slightly better patency compared with BECS/BMS, which contrasts with the results from the entire PERICLES group,33 in which the primary patency is better for BECS. However, the discrepancy is likely due to the small number of patients in the current analysis.

In our opinion, there are several strong points in favor of chEVAR. This technique is readily dispensable, meaning that even symptomatic and emergency type Ia endoleaks can be managed with this strategy. Access complications are few as a stent-graft with the same profile as the one implanted is used in the majority of cases. Cannulation of the target vessels from above is generally easy, especially in downward-oriented renal arteries, and not much influenced by the presence of a suprarenal stent. Furthermore, in cases of endoleak recurrence, a further reintervention with proximal extension or gutter embolization is feasible.12,30 Last but not least, suprarenal aortic coverage in chEVAR is generally short so that risk of paraplegia is low.

The chimney technique still has some issues such as parallel graft combinations, use of multiple stent-grafts, and main graft oversizing. Scalli et al33 reported that use of nitinol/polyester graft combinations, use of multiple stent-grafts, and mainer short so that risk of paraplegia is low.

When compared to the entire PERICLES registry,13 the results here are similar in terms of chimney patency (94.3% vs 94.1%) and incidence of immediate type Ia endoleak (92.3% vs 92.1%). While there was no difference in terms of performance among the aortic components, SECS showed slightly better patency compared with BECS/BMS, which contrasts with the results from the entire PERICLES group,33 in which the primary patency is better for BECS. However, the discrepancy is likely due to the small number of patients in the current analysis.

In our opinion, there are several strong points in favor of chEVAR. This technique is readily dispensable, meaning that even symptomatic and emergency type Ia endoleaks can be managed with this strategy. Access complications are few as a stent-graft with the same profile as the one implanted is used in the majority of cases. Cannulation of the target vessels from above is generally easy, especially in downward-oriented renal arteries, and not much influenced by the presence of a suprarenal stent. Furthermore, in cases of endoleak recurrence, a further reintervention with proximal extension or gutter embolization is feasible.12,30 Last but not least, suprarenal aortic coverage in chEVAR is generally short so that risk of paraplegia is low.

The chimney technique still has some issues such as parallel graft combinations, use of multiple stent-grafts, and main graft oversizing. Scalli et al33 reported that use of nitinol/polyester graft combinations, use of multiple stent-grafts, and repairs incorporating multiple chimney subtypes are associated with increased mortality risk. The data regarding main graft oversizing are improving thanks to in vitro studies that promoted 30% oversizing as the best option even for multiple parallel grafts. On the other hand, there is a custom method (“Oversizing”) in which the operators choose main graft oversizing directly on the CT scan during planning.34,35

**Conclusion**

Our experience demonstrates that the chimney technique is a safe and viable option to treat type Ia endoleak, with good midterm results, both for primary target vessel patency and resolution of endoleak. Results are independent of the used abdominal stent-grafts and chimney grafts combinations. The technique is certainly the best choice for urgent and/or emergency cases.

**Authors’ Note**

This study was presented as an abstract at the SVS Annual Vascular Meeting (May 31, 2017; San Diego, CA USA).

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Stefano Fazzini https://orcid.org/0000-0002-4028-4947

**References**

11. Jordan WD, Mehta M, Varnagy D, et al. Results of the ANCHOR prospective, multicenter registry of EndoAnchors...